Off the scrapheap of discarded drugs and on its way to becoming the most highly anticipated approval of 2024, Bristol Myers ...
The path to discovering a blockbuster drug is often unpredictable. A promising molecule might be overlooked for decades, only ...
Christopoulos, Dean of the Faculty of Pharmaceutical Sciences at Monash University, is at the centre of a significant ...
AbbVie's acquisition of Cerevel Therapeutics strengthens its neuroscience pipeline with promising candidates, making ABBV a ...
The rise in research and development activities in schizophrenia treatment is driving market growth by fostering the development of innovative therapies, including novel antipsychotics and ...
US pharma major Bristol Myers Squibb’s recent approval from the US Food and Drug Administration (FDA) for Cobenfy (xanomeline ...
Scientists now have greater insight into one of Schizophrenia's poorly understood hallmarks — auditory hallucinations.
The recent FDA approval of KarXT (Cobenfy), developed by Karuna Therapeutics (a subsidiary of Bristol Myers Squibb), marks a ...
For the first time in nearly 30 years, the U.S. Food and Drug Administration has approved a new drug treating schizophrenia, ...
Seroquel is a brand-name oral tablet that doctors prescribe for schizophrenia and certain types of bipolar disorder. It ...
A forensic psychiatrist for the defence in a murder trial believes the accused Wire Reddington was suffering from ...
For around 70 years, the treatment of schizophrenia has relied almost entirely on drugs that block dopamine receptors, so Cobenfy's action on cholinergic receptors offers a brand new way to treat ...